Charming Medical Limited share price

Charming Medical Limited's share price was $29.36 at the close on 11 November 2025. Since its first close in our records, on 24 October 2025, it has traded between $7 and $29, and at that close it was at the high of that range. There is not enough history yet to compare it with the S&P 500.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Charming Medical Limited is a new listing: we have 1 month of share prices so far, since 24 October 2025. The price chart, its averages and its phases need more history, so they appear once there is enough.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Charming Medical Limited pays no dividend. In the last 6 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Charming Medical Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Charming Medical Limited earned $50.0 K of net profit in the Mar 2026 quarter, −93.2% on the same quarter a year earlier. The full FY26 year was a loss of $23.0 K. That is 1.9% of the quarter's revenue. The same quarter a year earlier earned $403 K.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was −$23.0 K (−101.9% on the year before).

Why profit moved: revenue changed −18.8% on a year earlier and the margin moved −24.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −25.6% and revenue −9.3%. Profit is growing slower than sales: rising costs are taking part of the growth.

Charming Medical Limited reported $2.6 M of revenue in the Mar 2026 quarter, −18.8% on the same quarter a year earlier. Over 3 years it has grown 10.8% a year on average. The last full year, FY26, came in at $4.8 M.

Revenue is everything the company billed its customers in the period.

FY26 revenue was $4.8 M, −22.7% on the year before.

Recent pace: the last four quarters grew −9.3% on average, against 10.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Charming Medical Limited's operating margin was 4.9% in the Mar 2026 quarter, 24.0 percentage points lower than the same quarter a year ago. Over the last four quarters it has moved −14.2 percentage points. Across 4 years it has been between −10.7% and 25.7%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −14.2 percentage points on the year while gross margin changed +0.4 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 2 years, 36% of Charming Medical Limited's reported profit came in as cash from its operations, a gap worth watching. In FY26 its operations used $1.2 M of cash, against −$23.0 K of profit. After $340 K of spending on assets, free cash was −$1.6 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Charming Medical Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $839 K on assets over the last 3 years. Averaged over those years that is 5.8% of FY26 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $839 K over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Charming Medical Limited's P/E is 767.2×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple.

Charming Medical Limited's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Charming Medical Limited earned a ROE of 0% in FY26. That is up from a low of −68% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads 22%, a number that says nothing useful about the business. It comes from a −0.5% net margin and 0.49× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY26): a −0.5% net margin × 0.49× asset turnover × 1.90× leverage (assets divided by equity) ≈ −0.5% on equity. The margin does its share; borrowing is a big part of it.

Charming Medical Limited has total debt of $908 K against shareholder equity of $5.2 M as of Mar 2026, so its debt is 0.18× its equity, which is very little. Year by year, that ratio went from −1.43 in FY23 to 0.18 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

We have no ownership or short-position figures for Charming Medical Limited, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 2.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

For Charming Medical Limited, the Z-score is 40.59. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 40.59 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Charming Medical Limited is not among the largest members shown in this industry comparison for Medical Care Facilities.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Charming Medical Limited is the 34th largest of 38 Medical Care Facilities companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: U.S. Physical Therapy, Inc., GMR Solutions Inc. and The Oncology Institute, Inc. Just below it: Strata Critical Medical, Inc., Cross Country Healthcare, Inc. and Auna S.A.

Medical Care Facilities companies close in size

31. U.S. Physical Therapy, Inc. $1.3 billion
32. GMR Solutions Inc. $963 million
33. The Oncology Institute, Inc. $707 million
34. Charming Medical Limited $504 million
35. Strata Critical Medical, Inc. $466 million
36. Cross Country Healthcare, Inc. $428 million
37. Auna S.A. $343 million

All 38 Medical Care Facilities companies, largest first

Companies close in size in other industries

2842. Satellogic Inc. $506 million · Aerospace & Defense
2843. CoinShares PLC $505 million · Capital Markets
2844. Charming Medical Limited $504 million
2845. Investors Title Company $504 million · Insurance - Specialty
2846. TAT Technologies Ltd. $504 million · Aerospace & Defense

Sector Alpha, written by code from the published numbers. Data as of 11 November 2025.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.